4697
IRIREACT 3 MG/ML + 0.5 MG/ML EYE DROPS SOLUTION 1 10 ML LDPE DROPPER BOTTLE
IRIREACT 3 MG/ML + 0.5 MG/ML EYE DROPS SOLUTION 1 10 ML LDPE DROPPER BOTTLE
Secure payment
Discreet and sanitized package
Fast and safe shipping
Description
Description
Name
IRIREACT 3 mg/ml + 0.5 mg/ml eye drops, solution
Pheniramine maleate + Tetrizoline hydrochloride
Equivalent medicine
What is it and what is it used for?
IRIREACT contains the active substances pheniramine maleate and tetryzoline hydrochloride.
Pheniramine maleate belongs to a group of medicines called "antihistamines" and works by counteracting the symptoms of allergy.
Tetrizoline hydrochloride belongs to a group of medicines called "decongestants" and works by reducing the dilation of blood vessels.
IRIREACT is used to treat allergies and inflammation of the membrane of the eye (conjunctiva) accompanied by hypersensitivity to light (photophobia), tearing, foreign body sensation, and pain.
Contact your doctor if you do not feel better or if you feel worse after 4 days of treatment.
What you need to know before taking the medicine
Do not use IRIREACT:
- if you are allergic to pheniramine maleate or tetryzoline hydrochloride or any of the other ingredients of this medicine (listed in section 6);
- if you are allergic to other medicines of the same family as pheniramine maleate and tetryzoline hydrochloride, in particular xylometazoline, oxymetazoline, naphazoline;
- if you have a disease caused by high pressure inside the eye (narrow-angle glaucoma) or if you suffer from other serious eye diseases;
- if it is for a child under 12 years old;
- if you are pregnant or breastfeeding (see "Pregnancy and breastfeeding");
- if you are being treated at the same time with medicines used for depression (monoamine oxidase inhibitors, such as tranylcypromine, phenelzine, pargyline) (see "Other medicines and IRIREACT").
Warnings and precautions
Talk to your doctor or pharmacist before using IRIREACT:
- if you suffer from high blood pressure (hypertension);
- if you suffer from excessive activity of a gland called the thyroid (hyperthyroidism);
- if you have heart problems;
- if you have high blood sugar levels (hyperglycemia, diabetes);
- if you suffer from infections or pus in the eye;
- if you have foreign bodies in your eye;
- if you have eye problems of various kinds (mechanical, chemical, heat-related).
The use of topical medications, especially if prolonged, can cause allergies (sensitization phenomena). In this case, your doctor will ask you to discontinue treatment and recommend appropriate therapy.
Do not use this medicine for more than 4 consecutive days unless otherwise prescribed by your doctor, as this may cause side effects. IRIREACT in the multidose bottle contains benzalkonium chloride as a preservative, which may cause allergic reactions.
You should not wear contact lenses during treatment and may only put them in for 15 minutes after using the medicine. If you are allergic to benzalkonium chloride or wear contact lenses, you can use IRIREACT in the single-dose container that does not contain preservatives.
Children and adolescents
IRIREACT should not be used in children under 12 years of age.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
During treatment with IRIREACT you may experience allergic reactions. In this case, STOP treatment immediately and contact your doctor who, if necessary, will be able to give you appropriate treatment.
During treatment with IRIREACT you may also experience the following side effects:
Effects affecting the eye:
• pupil dilation;
• increased pressure inside the eye.
Effects that affect the whole organism:v • increase in blood pressure (hypertension);
• heart disorders;
• increased blood sugar levels (hyperglycemia);
• nausea;
• heachache.
If accidentally ingested in children, the preparation can cause a state of even profound drowsiness (somnolence) and decreased activity (hypotonia).
Hypersensitivity reactions may rarely occur. If this occurs, discontinue treatment and consult your doctor who, if necessary, will prescribe appropriate therapy.
Reporting of side effects
If you experience any side effects, including any not listed in this leaflet, talk to your doctor or pharmacist. You can also report side effects directly via the national reporting system at: https://www.aifa.gov.it/content/segnalazionireazioni-avverse .
By reporting side effects you can help provide more information on the safety of this medicine.
IRIREACT 3 mg/ml + 0.5 mg/ml eye drops, solution
Pheniramine maleate + Tetrizoline hydrochloride
Equivalent medicine
What is it and what is it used for?
IRIREACT contains the active substances pheniramine maleate and tetryzoline hydrochloride.
Pheniramine maleate belongs to a group of medicines called "antihistamines" and works by counteracting the symptoms of allergy.
Tetrizoline hydrochloride belongs to a group of medicines called "decongestants" and works by reducing the dilation of blood vessels.
IRIREACT is used to treat allergies and inflammation of the membrane of the eye (conjunctiva) accompanied by hypersensitivity to light (photophobia), tearing, foreign body sensation, and pain.
Contact your doctor if you do not feel better or if you feel worse after 4 days of treatment.
What you need to know before taking the medicine
Do not use IRIREACT:
- if you are allergic to pheniramine maleate or tetryzoline hydrochloride or any of the other ingredients of this medicine (listed in section 6);
- if you are allergic to other medicines of the same family as pheniramine maleate and tetryzoline hydrochloride, in particular xylometazoline, oxymetazoline, naphazoline;
- if you have a disease caused by high pressure inside the eye (narrow-angle glaucoma) or if you suffer from other serious eye diseases;
- if it is for a child under 12 years old;
- if you are pregnant or breastfeeding (see "Pregnancy and breastfeeding");
- if you are being treated at the same time with medicines used for depression (monoamine oxidase inhibitors, such as tranylcypromine, phenelzine, pargyline) (see "Other medicines and IRIREACT").
Warnings and precautions
Talk to your doctor or pharmacist before using IRIREACT:
- if you suffer from high blood pressure (hypertension);
- if you suffer from excessive activity of a gland called the thyroid (hyperthyroidism);
- if you have heart problems;
- if you have high blood sugar levels (hyperglycemia, diabetes);
- if you suffer from infections or pus in the eye;
- if you have foreign bodies in your eye;
- if you have eye problems of various kinds (mechanical, chemical, heat-related).
The use of topical medications, especially if prolonged, can cause allergies (sensitization phenomena). In this case, your doctor will ask you to discontinue treatment and recommend appropriate therapy.
Do not use this medicine for more than 4 consecutive days unless otherwise prescribed by your doctor, as this may cause side effects. IRIREACT in the multidose bottle contains benzalkonium chloride as a preservative, which may cause allergic reactions.
You should not wear contact lenses during treatment and may only put them in for 15 minutes after using the medicine. If you are allergic to benzalkonium chloride or wear contact lenses, you can use IRIREACT in the single-dose container that does not contain preservatives.
Children and adolescents
IRIREACT should not be used in children under 12 years of age.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
During treatment with IRIREACT you may experience allergic reactions. In this case, STOP treatment immediately and contact your doctor who, if necessary, will be able to give you appropriate treatment.
During treatment with IRIREACT you may also experience the following side effects:
Effects affecting the eye:
• pupil dilation;
• increased pressure inside the eye.
Effects that affect the whole organism:v • increase in blood pressure (hypertension);
• heart disorders;
• increased blood sugar levels (hyperglycemia);
• nausea;
• heachache.
If accidentally ingested in children, the preparation can cause a state of even profound drowsiness (somnolence) and decreased activity (hypotonia).
Hypersensitivity reactions may rarely occur. If this occurs, discontinue treatment and consult your doctor who, if necessary, will prescribe appropriate therapy.
Reporting of side effects
If you experience any side effects, including any not listed in this leaflet, talk to your doctor or pharmacist. You can also report side effects directly via the national reporting system at: https://www.aifa.gov.it/content/segnalazionireazioni-avverse .
By reporting side effects you can help provide more information on the safety of this medicine.
4697
IRIREACT 3 MG/ML + 0.5 MG/ML EYE DROPS SOLUTION 1 10 ML LDPE DROPPER BOTTLE
IRIREACT 3 MG/ML + 0.5 MG/ML EYE DROPS SOLUTION 1 10 ML LDPE DROPPER BOTTLE
MINSAN code: 047352024
Previous price: €9,90
Regular price
€9,90
Regular price
€0,00
Sale price
€9,90
Unit price
per
Tax included.
Shipping calculated at checkout.
Couldn't load pickup availability
Product images are purely indicative and may not be fully representative of the packaging and product features, as they may vary in color, size, or content. Any decorations, gift wrapping, and items included in the images for product presentation purposes will not be shipped with orders. Product names, ingredients, and percentages indicated in the descriptions are purely indicative and may be subject to change or updates by the manufacturers. Due to the impossibility of updating these updates in real time, the photos and technical information of the products listed on farmaInnovation.it may differ from those shown on the label or otherwise disclosed by the manufacturers. The only identifying element is the MINSAN (Ministry of Health) code. Farmacia Barni, farmainnovation.it , does not guarantee the accuracy and timeliness of the information published and declines all responsibility for any errors, omissions, or failure to update it. farmainnovation.it assumes no responsibility for damages of any kind that may arise from accessing the published information.
